In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
In the latest session, Exact Sciences Corp (NASDAQ: EXAS) closed at $54.63 down -0.44% from its previous closing price of $54.87. In other words, the price has decreased by -$0.44 from its previous closing price. On the day, 1.42 million shares were traded. EXAS stock price reached its highest trading level at $55.34 during the session, while it also had its lowest trading level at $53.61.
Ratios:
For a deeper understanding of Exact Sciences Corp’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 13.11 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 53.08. For the most recent quarter (mrq), Quick Ratio is recorded 2.38 and its Current Ratio is at 2.73. In the meantime, Its Debt-to-Equity ratio is 1.06 whereas as Long-Term Debt/Eq ratio is at 1.04.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Mizuho on April 10, 2025, initiated with a Outperform rating and assigned the stock a target price of $60.
On March 13, 2025, RBC Capital Mkts started tracking the stock assigning a Sector Perform rating and target price of $52.
On January 23, 2025, Barclays started tracking the stock assigning a Overweight rating and target price of $70.Barclays initiated its Overweight rating on January 23, 2025, with a $70 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Nov 13 ’24 when Conroy Kevin T bought 19,500 shares for $51.35 per share. The transaction valued at 1,001,325 led to the insider holds 1,074,191 shares of the business.
Baranick Brian sold 929 shares of EXAS for $65,030 on Oct 08 ’24. The EVP, GM, Precision Oncology now owns 12,758 shares after completing the transaction at $70.00 per share. On Oct 08 ’24, another insider, Baranick Brian, who serves as the Officer of the company, bought 929 shares for $70.00 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, EXAS now has a Market Capitalization of 10350527488 and an Enterprise Value of 12058184704. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.64 while its Price-to-Book (P/B) ratio in mrq is 4.30. Its current Enterprise Value per Revenue stands at 4.264 whereas that against EBITDA is 316.554.
Stock Price History:
The Beta on a monthly basis for EXAS is 0.98, which has changed by 0.29639292 over the last 52 weeks, in comparison to a change of 0.11730647 over the same period for the S&P500. Over the past 52 weeks, EXAS has reached a high of $72.83, while it has fallen to a 52-week low of $39.97. The 50-Day Moving Average of the stock is 9.61%, while the 200-Day Moving Average is calculated to be -2.59%.
Shares Statistics:
For the past three months, EXAS has traded an average of 2.80M shares per day and 3473210 over the past ten days. A total of 188.59M shares are outstanding, with a floating share count of 185.85M. Insiders hold about 1.48% of the company’s shares, while institutions hold 97.59% stake in the company. Shares short for EXAS as of 1747267200 were 11138144 with a Short Ratio of 3.98, compared to 1744675200 on 10732123. Therefore, it implies a Short% of Shares Outstanding of 11138144 and a Short% of Float of 6.75.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
